Upstream Bio Financials - Benzinga

Upstream Bio Inc

UPBNASDAQ

Trade with Public

Trade with Public

$5.36

0.193.68%

가까이에: Sep 25, 5:00 PM EST

$5.34

-0.02-0.37%

시간외: 6:11 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Upstream Bio Financials

Upstream Bio (UPB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the

Benzinga Newsdesk

PRO
Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 47.06 percent decrease over losses of $(0.51) per share from the

Benzinga Newsdesk

Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.

Vandana Singh

PRO
Upstream Bio Q3 EPS $(0.63) Beats $(0.76) Estimate, Sales $683.000K Beat $645.000K Estimate

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.76) by 17.54 percent. This is a 90.95 percent increase over losses of $(6.96) per share from the

Benzinga Newsdesk

PRO
Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,

Benzinga Newsdesk

PRO
Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved